All In Biotech

Drug Trial Radar · NCT01270464

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

Last checked: Nov 20, 2026Latest source record: Jun 6, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 315 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

315

Actual

Start

Feb 2011

Primary completion

Sep 2013

Study completion Sep 2013

Sponsor

Sponsor type
Industry
First posted
Jan 5, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic asthma as assessed by the overall change from baseline in forced expiratory volume in 1 second (FEV1).

Conditions

  • Eosinophilic Asthma

Interventions

  • ReslizumabDrug

    3.0 mg/kg or 0.3 mg/kg doses administered intravenously (iv) by qualified site personnel once every 4 weeks, for a total of 4 doses.

  • PlaceboDrug

    Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed Model for Repeated MeasuresTime frame: Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16

Locations

89 sites in 13 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 12

    Anaheim, California

  • Teva Investigational Site 11

    Fountain Valley, California

  • Teva Investigational Site 43

    Los Angeles, California

  • Teva Investigational Site 4

    Orange, California

  • Teva Investigational Site 15

    Walnut Creek, California

  • Teva Investigational Site 2

    Colorado Springs, Colorado

  • Teva Investigational Site 24

    Largo, Florida

  • Teva Investigational Site 27

    Miami, Florida

  • Teva Investigational Site 5

    Miami, Florida

  • Teva Investigational Site 19

    Tallahassee, Florida

  • Teva Investigational Site 17

    Trinity, Florida

  • Teva Investigational Site 18

    Valrico, Florida

  • Teva Investigational Site 6

    Lilburn, Georgia

  • Teva Investigational Site 3

    Savannah, Georgia

  • Teva Investigational Site 7

    Iowa City, Iowa

  • Teva Investigational Site 8

    Omaha, Nebraska

  • Teva Investigational Site 26

    Summit, New Jersey

  • Teva Investigational Site 20

    Cincinnati, Ohio

  • Teva Investigational Site 1

    Medford, Oregon

  • Teva Investigational Site 73

    Lincoln, Rhode Island

  • Teva Investigational Site 9

    Providence, Rhode Island

  • Teva Investigational Site 21

    Charleston, South Carolina

  • Teva Investigational Site 16

    Fort Worth, Texas

  • Teva Investigational Site 10

    Houston, Texas

  • Teva Investigational Site 14

    San Antonio, Texas

  • Teva Investigational Site 45

    San Antonio, Texas

  • Teva Investigational Site 121

    Ciudad Autonoma de Buenos Aire, Argentina

  • Teva Investigational Site 126

    Ciudad Autonoma de Buenos Aire, Argentina

  • Teva Investigational Site 127

    Ciudad Autonoma de Buenos Aire, Argentina

  • Teva Investigational Site 128

    Quilmes-Buenos Aires, Argentina

  • Teva Investigational Site 125

    Rosario, Argentina

  • Teva Investigational Site 123

    Rosario-Santa Fe, Argentina

  • Teva Investigational Site 120

    San Miguel de Tucuman - Tucuma, Argentina

  • Teva Investigational Site 122

    San Miguel de Tucuman - Tucuma, Argentina

  • Teva Investigational Site 124

    San Miguel de Tucuman - Tucuma, Argentina

  • Teva Investigational Site 261

    Brussels, Belgium

  • Teva Investigational Site 264

    Brussels, Belgium

  • Teva Investigational Site 260

    Ghent, Belgium

  • Teva Investigational Site 263

    Liège, Belgium

  • Teva Investigational Site 146

    Belo Horizonte, Brazil

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.